Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential
Molecular Psychiatry – October 21, 2025
Source: OpenAlex
Summary
A novel compound, 5-Br-DMT, shows promise as a rapid-acting antidepressant without hallucinogenic effects. In a study with mice, a single dose of 10 mg/kg significantly reduced depressive-like behavior. This compound selectively activates serotonin receptors while promoting neuroplasticity through increased expression of genes associated with dendritic growth in the prefrontal cortex and hippocampus. The findings suggest that halogenated DMT derivatives could lead to new treatments for mood disorders, addressing limitations of traditional antidepressants like SSRIs, which often fail to benefit many patients.
Abstract
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to effectively treat a large proportion of patients, leaving a gap in the treatment of mood disorders. Psychedelics have recently emerged as promising alternatives due to their ability to produce fast-acting antidepressant effects through neuroplastic adaptations, but their hallucinogenic properties remain a major obstacle to their widespread therapeutic use. In this study, we characterized a novel class of halogenated DMT derivatives-5-F-DMT, 5-Cl-DMT, and 5-Br-DMT-for their pharmacological activity, behavioral effects, and therapeutic potential. Using a combination of in vitro assays, in silico modeling, and in vivo behavioral and gene expression studies, we found that halogen substitution at the 5-position modulates receptor affinity and selectivity across key serotonin (5-HT) receptors (5-HT1A/2 A/2B/2CR) and transporter (SERT). Notably, 5-Br-DMT was found to activate 5-HT2AR but did not induce the head twitch response (HTR) in mice, suggesting non-hallucinogenic activity. Furthermore, 5-Br-DMT upregulated immediate early genes (IEGs) associated with neuroplasticity in the mouse prefrontal cortex and hippocampus (Arc, Egr-1, -2 and -3) and promoted dendritic growth in cortical neurons. In a mouse model of stress-induced depression, a single administration (10 mg/kg, i.p.) of 5-Br-DMT resulted in a significant reduction in depressive-like behavior, reflecting rapid antidepressant effects. Collectively, our results highlight 5-Br-DMT as a non-hallucinogenic psychoplastogen with antidepressant properties, supporting its potential as a prototypical candidate for further study. Moreover, the evaluation and biological characterization of the halogenated DMT derivatives offers valuable information on structure-activity relationships that may guide the design of future therapeutic compounds.